Literature DB >> 23069119

The impact of newborn screening and earlier intervention on the clinical course of cystic fibrosis.

F Nicole Dijk1, Dominic A Fitzgerald.   

Abstract

Cystic fibrosis is a life-limiting condition which is readily diagnosed in the vast majority of cases on newborn screening [NBS]. A diagnosis made on newborn screening translates into earlier initiation of therapies, improved growth, better lung function into the adult years and culminates in better survival. Crown
Copyright © 2012. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Year:  2012        PMID： 23069119     DOI： 10.1016/j.prrv.2012.05.003

Source DB:  PubMed          Journal:  Paediatr Respir Rev        ISSN： 1526-0542            Impact factor:   2.726


  12 in total

1.  Growth in Prepubertal Children With Cystic Fibrosis Treated With Ivacaftor.

Authors:  Michael S Stalvey; Jesse Pace; Minoo Niknian; Mark N Higgins; Valerie Tarn; Joy Davis; Sonya L Heltshe; Steven M Rowe
Journal:  Pediatrics       Date:  2017-02       Impact factor: 7.124

Review 2.  Role for animal models in understanding essential fatty acid deficiency in cystic fibrosis.

Authors:  Deanne H Hryciw; Courtney A Jackson; Nirajan Shrestha; David Parsons; Martin Donnelley; Andrew J McAinch
Journal:  Cell Mol Life Sci       Date:  2021-11-05       Impact factor: 9.261

3.  Next-Generation Molecular Testing of Newborn Dried Blood Spots for Cystic Fibrosis.

Authors:  Martina I Lefterova; Peidong Shen; Justin I Odegaard; Eula Fung; Tsoyu Chiang; Gang Peng; Ronald W Davis; Wenyi Wang; Martin Kharrazi; Iris Schrijver; Curt Scharfe
Journal:  J Mol Diagn       Date:  2016-02-01       Impact factor: 5.568

4.  S737F is a new CFTR mutation typical of patients originally from the Tuscany region in Italy.

Authors:  Vito Terlizzi; Antonella Miriam Di Lullo; Marika Comegna; Claudia Centrone; Elisabetta Pelo; Giuseppe Castaldo; Valeria Raia; Cesare Braggion
Journal:  Ital J Pediatr       Date:  2018-01-03       Impact factor: 2.638

5.  Optimization of the French cystic fibrosis newborn screening programme by a centralized tracking process.

Authors:  Anne Munck; Dominique Delmas; Marie-Pierre Audrézet; Lydie Lemonnier; David Cheillan; Michel Roussey
Journal:  J Med Screen       Date:  2017-04-28       Impact factor: 2.136

6.  Sweat test and cystic fibrosis: overview of test performance at public and private centers in the state of São Paulo, Brazil.

Authors:  Maria Fátima Servidoni; Carla Cristina Souza Gomez; Fernando Augusto Lima Marson; Adyléia Aparecida Dalbo Contrera Toro; Maria Ângela Gonçalves de Oliveira Ribeiro; José Dirceu Ribeiro; Antônio Fernando Ribeiro
Journal:  J Bras Pneumol       Date:  2017 Mar-Apr       Impact factor: 2.624

7.  Newborn Screening Quality Assurance Program for CFTR Mutation Detection and Gene Sequencing to Identify Cystic Fibrosis.

Authors:  Miyono M Hendrix; Stephanie L Foster; Suzanne K Cordovado
Journal:  J Inborn Errors Metab Screen       Date:  2016-08-01

8.  Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry data.

Authors:  Ruth H Keogh; Rhonda Szczesniak; David Taylor-Robinson; Diana Bilton
Journal:  J Cyst Fibros       Date:  2018-01-06       Impact factor: 5.482

9.  Screening for cystic fibrosis in New York State: considerations for algorithm improvements.

Authors:  Denise M Kay; Breanne Maloney; Rhonda Hamel; Melissa Pearce; Lenore DeMartino; Rebecca McMahon; Emily McGrath; Lea Krein; Beth Vogel; Carlos A Saavedra-Matiz; Michele Caggana; Norma P Tavakoli
Journal:  Eur J Pediatr       Date:  2015-08-21       Impact factor: 3.183

Review 10.  CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis.

Authors:  Miquéias Lopes-Pacheco
Journal:  Front Pharmacol       Date:  2016-09-05       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.